Invasive meningococcal disease epidemiology and vaccination strategies in four Southern European countries: a review of the available data

References

• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20.
   PubMedGoogle Scholar
• Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397–403. DOI:10.1016/S0140-6736(06)67932-4
   PubMed Web of Science ®Google Scholar
• Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(Suppl 2):B3–9. doi: 10.1016/j.vaccine.2011.12.062
   PubMed Web of Science ®Google Scholar
• Stein-Zamir C, Shoob H, Sokolov I, et al. The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J. 2014;33(7):777–779. DOI:10.1097/INF.0000000000000282
   PubMed Web of Science ®Google Scholar
• Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–498. DOI:10.1016/j.jinf.2020.05.079
   PubMed Web of Science ®Google Scholar
• Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(2 Suppl):S3–s11. doi: 10.1016/j.jadohealth.2016.04.012
   PubMed Web of Science ®Google Scholar
• Gabutti G, Stefanati A, Kuhdari P. Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage. J Prev Med Hyg. 2015;56(3):E116–E120.
   PubMedGoogle Scholar
• Spyromitrou-Xioufi P, Tsirigotaki M, Ladomenou F. Risk factors for meningococcal disease in children and adolescents: a systematic review and Meta-analysis. Eur J Pediatr. 2020;179(7):1017–1027. doi: 10.1007/s00431-020-03658-9
   PubMed Web of Science ®Google Scholar
• Taha MK, Weil-Olivier C, Bouee S, et al. Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother. 2021;17(6):1858–1866. DOI:10.1080/21645515.2020.1849518
   PubMed Web of Science ®Google Scholar
• World Health Organization, Meningitis. [cited 2021 Oct 25]. Available from: https://www.who.int/news-room/fact-sheets/detail/meningitis.
   Google Scholar
• Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134:103571.
   PubMed Web of Science ®Google Scholar
• Findlow J, Lucidarme J, Taha MK, et al. Correlates of protection for meningococcal surface protein vaccines: lessons from the past. Expert Rev Vaccines. 2022;21(6):739–751. doi: 10.1080/14760584.2021.1940144.
   PubMed Web of Science ®Google Scholar
• MacDonald NE, Halperin SA, Law BJ, et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers a randomized controlled trial. JAMA. 1998;280(19):1685–1689. DOI:10.1001/jama.280.19.1685
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews NJ, Trotter C, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326(7385):365–366. DOI:10.1136/bmj.326.7385.365
   PubMed Web of Science ®Google Scholar
• Maiden MCJ, Ibarz-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737–743. DOI:10.1086/527401
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2(8346):355–357. doi: 10.1016/S0140-6736(83)90340-9
   PubMed Web of Science ®Google Scholar
• Wyle FA, Artenstein MS, Brandt BL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972;126(5):514–522. DOI:10.1093/infdis/126.5.514
   PubMed Web of Science ®Google Scholar
• Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72(4):2088–2100. DOI:10.1128/IAI.72.4.2088-2100.2004
   PubMed Web of Science ®Google Scholar
• Schneider MC, Exley RM, Chan H, et al. Functional Significance Of Factor H Binding to Neisseria meningitidis. J Immunol. 2006;176(12):7566–7575. DOI:10.4049/jimmunol.176.12.7566
   PubMed Web of Science ®Google Scholar
• Hoiseth SK, Murphy E, Andrew L, et al. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J. 2013;32(10):1096–1101. DOI:10.1097/INF.0b013e31829aa63b
   PubMed Web of Science ®Google Scholar
• Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200(3):379–389. DOI:10.1086/600141
   PubMed Web of Science ®Google Scholar
• McNeil LK, Donald RGK, Gribenko A, et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rlp2086, a novel prophylactic vaccine. MBio. 2018;9(2):e00036–18. DOI:10.1128/mBio.00036-18
   PubMed Web of Science ®Google Scholar
• Findlow J, Bayliss CD, Beernink PT, et al. Broad vaccine protection against Neisseria meningitidis using factor H binding protein. Vaccine. 2020;38(49):7716–7727. doi: 10.1016/j.vaccine.2020.08.031.
   PubMed Web of Science ®Google Scholar
• Richmond PC, Nissen MD, Marshall H, et al. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine. 2012;30(43):6163–6174. DOI:10.1016/j.vaccine.2012.07.065
   PubMed Web of Science ®Google Scholar
• Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(8):597–607. DOI:10.1016/S1473-3099(12)70087-7
   PubMed Web of Science ®Google Scholar
• Nissen MD, Marshall HS, Richmond PC, et al. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J. 2013;32(4):364–371. DOI:10.1097/INF.0b013e31827b0d24
   PubMed Web of Science ®Google Scholar
• Marshall HS, Richmond PC, Nissen MD, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine. 2013;31(12):1569–1575. DOI:10.1016/j.vaccine.2013.01.021
   PubMed Web of Science ®Google Scholar
• Frosi G, Biolchi A, Lo Sapio M, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31(43):4968–4974. DOI:10.1016/j.vaccine.2013.08.006
   PubMed Web of Science ®Google Scholar
• Bexsero. Summary of Product Characteristics [cited 2021 Oct 25]. Available from: https://www.ema.europa.eu/en/documents/product-information/bexsero-epar-product-information_en.pdf.
   Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28(37):6086–6093. DOI:10.1016/j.vaccine.2010.06.083
   PubMed Web of Science ®Google Scholar
• Brehony C, Wilson DJ, Maiden MCJ. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology (Reading). 2009;155(Pt 12):4155–4169. doi: 10.1099/mic.0.027995-0
   PubMedGoogle Scholar
• Serruto D, Bottomley Matthew J, Sanjay R, et al. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30(Suppl 2):B87–B97. DOI:10.1016/j.vaccine.2012.01.033
   PubMed Web of Science ®Google Scholar
• Masignani V, Pizza M, Moxon ER. The development of a vaccine against meningococcus B using reverse vaccinology. Front Immunol. 2019;10(751). doi: 10.3389/fimmu.2019.00751.
   PubMedGoogle Scholar
• Křížová P, Musílek M, Vacková Z, et al. Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic. Epidemiol Mikrobiol Imunol. 2014;63(2):103–106.
   PubMed Web of Science ®Google Scholar
• Vogel U, Taha MK, Vazquez J, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13(5):416–425. DOI:10.1016/S1473-3099(13)70006-9
   PubMed Web of Science ®Google Scholar
• Rodrigues CMC, Jolley KA, Smith A, et al. Meningococcal Deduced Vaccine Antigen Reactivity (MenDevar) Index: a rapid and accessible tool that exploits genomic data in public health and clinical microbiology applications. J Clin Microbiol. 2020;59(1):e02161–20. doi: 10.1128/JCM.02161-20.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Defeating meningitis by 2030: a global road map. [cited 2021 Nov 16]. Available from: https://www.who.int/publications/i/item/9789240026407.
   Google Scholar
• Instituto Superior di Sanita, Invasive bacterial disease surveillance reports. [cited 2021 Jul 29]. Available from: https://www.iss.it/sn-mbi-rapporti-iss.
   Google Scholar
• Ministry of Health of Italy, National vaccination plan 2005–2007. [cited 2021 Jul 30]. Available from: https://www.salute.gov.it/imgs/C_17_pubblicazioni_543_allegato.pdf.
   Google Scholar
• Ministry of Health of Italy, National vaccination plan 2008–2010. [cited 2021 Jul 28]. Available from: http://www.ccm-network.it/documenti_Ccm/convegni/SANIT/materiali2008/25.6/6-Piano_Nazionale_Vaccini_Ricciardi.pdf.
   Google Scholar
• Ministry of Health of Italy, National vaccination plan 2012–2014. [cited 2021 Jul 30]. Available from: https://www.salute.gov.it/imgs/C_17_pubblicazioni_1721_allegato.pdf.
   Google Scholar
• Ministry of Health of Italy, National vaccination plan 2017–2019. [cited 2021 Jul 30]. Available from: https://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf.
   Google Scholar
• Bollettino Ufficiale della Regione Sicilia D.A n 1965/2017. [cited 2021 Jul 28]. Available from: http://pti.regione.sicilia.it/portal/page/portal/PIR_PORTALE/PIR_LaStrutturaRegionale/PIR_AssessoratoSalute/PIR_Infoedocumenti/PIR_DecretiAssessratoSalute/PIR_DecretiAssessoriali/PIR_DecretiAssessorialianno2017/D.A._n%B0_1965%5B1%5D%20-%20serv.4.pdf.
   Google Scholar
• Bollettino Ufficiale della Regione Puglia. n. 77 del. 11-Jun-2018[cited 2021 Jun 11]. Available from . http://burp.regione.puglia.it/documents/10192/19676300/Bollettino+numero+77±+Ordinario±+anno+2018/fff50b03-4743-4414-9d5a-d7aee8252ec3;jsessionid=5028E63241FAEC36BC69C395FA33D7D8
   Google Scholar
• Bollettino Ufficiale della Regione Campania - n. 20 del 08-42019. [cited 2021 Jul 28]. Available from: https://www.aiopcampania.it/public/normativa/4b06bd76312d445d85b9f8caa6082a8b.pdf.
   Google Scholar
• Simões MJ, BettencourtC, FernandesT. Doença invasiva meningocócica em Portugal - Vigilância epidemiológica integrada, 2003-2020: relatório anual da Rede de Laboratórios VigLab Doença Meningocócica. Instituto Nacional de Saúde Doutor Ricardo Jorge, IP 2022 http://hdl.handle.net/10400.18/8254 .
   Google Scholar
• Gabinete do Secretário de Estado da Saúde Despacho n.º 12434/2019. Aprova o novo esquema vacinal do Programa Nacional de Vacinação. [cited 2021 Jul 28]. Available from: https://dre.pt/application/conteudo/127608823.
   Google Scholar
• DGS, Programa Nacional de Vacinação 2006. Circular Normativa 08/DT de 21/12/2005, Direcção Geral de Saúde, Ministério da Saúde; 2005. [cited 2021 Jul 19].
   Google Scholar
• Ministry of Health and Social Solidarity, National Immunization Programmes. [cited 2021 Jul 30]. Available from: https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/metadotika-kai-mh-metadotika-noshmata/ethnika-programmata-emboliasmwn.
   Google Scholar
• Ministry of Health and Social Solidarity, General directorate of Public Health. Directorate of Public Hygiene, Department of disease epidemiology. Circular Υ1/Γ.Π. 17234, 14/6/2006 New National Immunization Programme. [cited 2021 Jul 19].
   Google Scholar
• Ministry of Health and Social Solidarity, General directorate of Public Health. Directorate of Public Hygiene, Department of disease epidemiology. Circular Υ1/Γ.Π.οικ.140202, 20/12/2011. New National Immunization Programme for children and adolescents 2011. [cited 2021 Jul 19].
   Google Scholar
• National Meningitis Reference Laboratory, annual reports 2010-2020. [cited 2021 Jul 28]. Available from: https://eelno.uniwa.gr/monada-ergastiriakis-epitirisis-tis-vaktiriakis-miniggitidas/#apologismoiekam.
   Google Scholar
• Instituto de salud Carlos III - RENAVE, Enfermedad meningocócica. Resultados de la vigilancia [cited 2021 Jul 29]. Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/Resultados_Vigilancia_Enfer_Meningo.aspx.
   Google Scholar
• Ministerio de Sanidad, Calendarios de vacunación en España 1975 - 2015. [cited 2021 Jul 30]. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/calendario-y-coberturas/calendario/docs/CalendariosVacunacion1975_2015.pdf.
   Google Scholar
• Ministerio de Sanidad, C.y.B.S, Recomendaciones de vacunación frente a la enfermedad meningocócica invasiva. 2019. [cited 2021 Jul 30]. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Recomendaciones_Vacunacion_Meningococo.pdf.
   Google Scholar
• Calendario de vacunación a lo largo de la vida 2021. [cited 2021 Jul 19]. Available from: https://www.sanidad.gob.es/profesionales/saludPublica/.
   Google Scholar
• Andalucia. Calendario de Vacunaciones. [cited 2021 Jul 30]. Available from: https://www.juntadeandalucia.es/organismos/saludyfamilias/areas/salud-vida/vacunas/paginas/calendario-vacunacion.html.
   Google Scholar
• Castilla y Leon. Calendario vacunal para toda la vida. [cited 2021 Jul 30]. Available from: https://www.saludcastillayleon.es/profesionales/es/vacunaciones/calendario-vacunal-toda-vida.
   Google Scholar
• Canarias. Nuevo Calendario vacunal para todas las edades de la vida. [cited 2021 Jul 29]. Available from: https://www3.gobiernodecanarias.org/sanidad/scs/contenidoGenerico.jsp?idDocument=3cc62be0-9746-11e0-ba66-75bd8cf93e41&idCarpeta=f60021f6-6ad8-11e2-bc0c-6512fc1bab5e.
   Google Scholar
• Boletín Oficial de la Junta de Andalucía. Número 36 - Martes, 23 de febrero de 2021. [cited 2021 Jul 29]. Available from: https://www.juntadeandalucia.es/boja/2021/36/BOJA21-036-00002-2748-01_00186669.pdf.
   Google Scholar
• Ministero della Salute, DIREZIONE GENERALE DELLA PREVENZIONE SANITARIA. UFFICIO 5 – PREVENZIONE DELLE MALATTIE TRASMISSIBILI E PROFILASSI INTERNAZIONALE. [cited 2021 Dec 15]. Available from: https://www.iss.it/documents/20126/0/Circolare_su_prevenzione_e_controllo_delle_malattie_batteriche_invasive_prevenibili_con_vaccinazione_2017.pdf/617b3ec6-fddc-fc76-1eda-e9db0700624a?t=1616751347702,2017.
   Google Scholar
• Simões MJ, Martins JV, Doença invasiva meningocócica em Portugal – Vigilância epidemiológica integrada, 2007-2016. [cited 2021 Dec 15]. Available from: https://www.sip-spp.pt/media/5vwgpwwr/insa_doenca_invasiva_meningococica_2007-2016.pdf.
   Google Scholar
• Tzanakaki G, ΕΘΝΙΚΟ ΚΕΝΤΡΟ ΑΝΑΦΟΡΑΣ ΜΗΝΙΓΓΙΤΙΔΑΣ. ΠΑΡΕΧΟΜΕΝΕΣ ΥΠΗΡΕΣΙΕΣ ΚΑΙ ΟΔΗΓΙΕΣ ΑΠΟΣΤΟΛΗΣ ΔΕΙΓΜΑΤΩΝ [cited 2021 Dec 15]. Available from: https://eelno.uniwa.gr/wp-content/uploads/sites/388/2020/06/%CE%A5%CE%A0%CE%97%CE%A1%CE%95%CE%A3-%CE%9C%CE%97%CE%9D%CE%99%CE%93%CE%93.pdf.
   Google Scholar
• Tzanakaki G, Xirogianni A, Tsitsika A, et al. Estimated strain coverage of serogroup B meningococcal vaccines: a retrospective study for disease and carrier strains in Greece (2010-2017). Vaccine. 2021;39(11):1621–1630. DOI:10.1016/j.vaccine.2021.01.073
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad, Real Decreto 2210/1995, de 28 de diciembre, por el que se crea la red nacional de vigilancia epidemiológica. [cited 2021 Dec 15]. Available from: https://www.boe.es/buscar/act.php?id=BOE-A-1996-1502.
   Google Scholar
• Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: bIGSdb software, the PubMLST.Org website and their applications. Wellcome Open Res. 2018;3:124. doi: 10.12688/wellcomeopenres.14826.1
   PubMedGoogle Scholar
• Carannante A, Fazio C, Neri A, et al. Meningococcal B vaccine antigen FHbp variants among disease-causing Neisseria meningitidis B isolates, Italy, 2014–2017. PLoS ONE. 2020;15(11):e0241793. DOI:10.1371/journal.pone.0241793
   PubMed Web of Science ®Google Scholar
• National Meningitis Reference Laboratory, annual reports 2018-2019. [cited 2021 Jul 28]. Available from: https://eelno.uniwa.gr/monada-ergastiriakis-epitirisis-tis-vaktiriakis-miniggitidas/#apologismoi_ekam.
   Google Scholar
• Abad R, Garcia-Amil C, Navarro C, et al. Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: evolution of the vaccine antigen factor H binding protein (FHbp). J Infect. 2021;82(4):37–44. DOI:10.1016/j.jinf.2021.01.030
   PubMed Web of Science ®Google Scholar
• Bollettino Ufficiale della Regione Puglia n. 149 del 30-12-2017. [cited 2022 Sep 12]. Available from: https://www.vaccinarsinpuglia.org/assets/uploads/files/191/legge-regionale-n.67-del-2017-art-60.pdf.
   Google Scholar
• Sezione Promozione della Salute e del Benessere, Legge regionale n. 67 del 29-122019. [cited 2022 Sep 12]. Available from: https://www.vaccinarsinpuglia.org/assets/uploads/files/191/nota-prot.-aoo152-135.pdf.
   Google Scholar
• Gazzetta Ufficiale della regione Sicilia. Anno 71°. Numero. 49. [cited 2022 Sep 12]. Available from http://www.gurs.regione.sicilia.it/Gazzette/g17-49/g17-49.pdf
   Google Scholar
• Decreto N 28 del 25-03-2019. Regione Campania. [cited 2022 Sep 12]. Available from: http://www.aiopcampania.it/public/normativa/4b06bd76312d445d85b9f8caa6082a8b.pdf.
   Google Scholar
• Delibere della Regione Basilicata Anno 2021. [cited 2022 Sep 12]. Available from: http://opservice.regione.basilicata.it/opendata-cma/ServletDocumentAtti?idAllegato=795801307B5906377C5102&idDocumento=795801307B5903357F5C.
   Google Scholar
• Decreto della Regione Calabria N. 32 DEL 07 APRILE 2022. https://www.regione.calabria.it/website/portalmedia/decreti/2022-04/DCA-n.32-del-7.4.2022.pdf. [cited 2022 Sep 12]. Available from.
   Google Scholar
• Delibera Regione Lazio U.0626754.29-07-2019 [cited 2022 Sep 12] Available from https://www.aslroma2.it/attachments/article/311/Prot_0626754_Circolare%20Vaccini_pediatri.pdf
   Google Scholar
• Leon, J.d.C.y, Calendario vacunal para toda la vida de Castilla y León. [cited 2022 Sep 12]. Available from: https://www.saludcastillayleon.es/profesionales/en/vacunaciones/calendario-vacunal-toda-vida-castilla-leon.
   Google Scholar
• Salud, S.C.d.l., Nuevo Calendario vacunal para todas las edades de la vida. [cited 2022 Sep 12]. Available from: https://www3.gobiernodecanarias.org/sanidad/scs/contenidoGenerico.jsp?idDocument=3cc62be0-9746-11e0-ba66-75bd8cf93e41&idCarpeta=b25ca6dc-a9a4-11dd-b574-dd4e320f085c.
   Google Scholar
• Familias, J.d.A.-C.d.S.y, Calendario de Vacunaciones 2022. [cited 2022 Sep 12]. Available from: https://www.andavac.es/calendario-vacunaciones/.
   Google Scholar
• Catalunya GD, La vacuna contra el meningococo B se incluye en el calendario de vacunaciones. [cited 2022 Sep 12]. Available from: https://web.gencat.cat/es/actualitat/detall/La-vacuna-contra-el-meningococ-B-sinclou-al-calendari-de-vacunacions.
   Google Scholar
• Catalunya GD, Calendari de vacunacions. [cited 2022 Sep 12]. Available from: https://canalsalut.gencat.cat/ca/salut-a-z/v/vacunacions/calendari/.
   Google Scholar
• Ciudad Aútonoma de Melilla. [cited 2022 Sep 13]. Available from: https://www.melilla.es/melillaPortal/RecursosWeb/DOCUMENTOS/1/0_26083_1.pdf.
   Google Scholar
• Murcia Salud. [cited 2022 Sep 13]. Available from: https://www.murciasalud.es/pagina.php?id=399382&idsec=824#.
   Google Scholar
• Govern Illes Balears. Calendario común de vacunación a lo largo de toda la vida en las Illes Balears 2022. [cited 2022 Sep 13] Available from: https://www.caib.es/sites/vacunacions/es/calendario_de_vacunacion_a_lo_largo_de_toda_la_vida/.
   Google Scholar
• Trumenba. Summary of product characteristics. [cited 2021 Oct 25]. Available from: https://www.ema.europa.eu/en/documents/product-information/trumenba-epar-product-information_en.pdf.
   Google Scholar
• ECDC, Invasive meningococcal disease: annual Epidemiological Report for 2017. [cited 2021 Nov 11]. Available from: https://www.ecdc.europa.eu/en/meningococcal-disease/surveillance-and-disease-data/aer.
   Google Scholar
• ECDC, Surveillance Atlas of Infectious Diseases. [cited 2021 Nov 1]. Available from: https://www.ecdc.europa.eu/en/meningococcal-disease/surveillance-and-disease-data/atlas.
   Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129(6):1327–1348. doi: 10.1084/jem.129.6.1327
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine. 2001;19(11–12):1327–1346. doi: 10.1016/S0264-410X(00)00333-9
   PubMed Web of Science ®Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect. 2006;134(3):556–566. doi: 10.1017/S0950268805005339
   PubMed Web of Science ®Google Scholar
• Bruce MG, Rosenstein NE, Capparella JM, et al. Risk factors for meningococcal disease in college students. JAMA. 2001;286(6):688–693. DOI:10.1001/jama.286.6.688
   PubMed Web of Science ®Google Scholar
• Imrey PB, Jackson LA, Ludwinski PH, et al. Outbreak of serogroup C meningococcal disease associated with campus bar patronage. Am J Epidemiol. 1996;143(6):624–630. DOI:10.1093/oxfordjournals.aje.a008792
   PubMed Web of Science ®Google Scholar
• Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445–450. DOI:10.1136/bmj.38725.728472.BE
   PubMedGoogle Scholar
• van Ravenhorst MB, Bijlsma MW, van Houten MA, et al. Meningococcal carriage in Dutch adolescents and young adults; a cross-sectional and longitudinal cohort study. Clin Microbiol Infect. 2017;23(8):e573.1–.e573.7. doi: 10.1016/j.cmi.2017.02.008
   Web of Science ®Google Scholar
• Whittaker R, Gomez Dias J, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. Vaccine. 2017;35(16):2034–2041. doi: 10.1016/j.vaccine.2017.03.007.
   PubMed Web of Science ®Google Scholar
• DGS, Campanha de vacinação contra a doença invasiva por Neisseria meningitidis do serogrupo C. Circular Normativa 09/DT de 22/12/05, Direcção Geral de Saúde, Ministério da Saúde; 2005. [cited 2021 Jul 19].
   Google Scholar
• Flountzi A, Georgakopoulou T, Balasegaram S, et al. Epidemiology of invasive meningococcal disease in Greece, 2006-2016. Eur J Clin Microbiol Infect Dis. 2019;38(12):2197–2203. DOI:10.1007/s10096-019-03668-y
   PubMed Web of Science ®Google Scholar
• Stefanelli P, Miglietta A, Pezzotti P, et al. Increased incidence of invasive meningococcal disease of serogroup C/clonal complex 11, Tuscany, Italy, 2015 to 2016. Euro Surveill. 2016;21(12). doi: 10.2807/1560-7917.ES.2016.21.12.30176
   PubMedGoogle Scholar
• Pezzotti P, Bellino S, Riccardo F, et al. Vaccine preventable invasive bacterial diseases in Italy: a comparison between the national surveillance system and recorded hospitalizations, 2007-2016. Vaccine. 2019;37(1):41–48. DOI:10.1016/j.vaccine.2018.11.047
   PubMed Web of Science ®Google Scholar
• ECDC, Vaccine scheduler. meningococcal disease: recommended vaccinations. [cited 2021 Nov 20]. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1.
   Google Scholar
• Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the meningococcal reference Unit. J Med Microbiol. 2006;55(7):887–896. DOI:10.1099/jmm.0.46288-0
   PubMed Web of Science ®Google Scholar
• Larrauri A, Cano R, Garcia M, et al. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23(32):4097–4100. DOI:10.1016/j.vaccine.2005.03.045
   PubMed Web of Science ®Google Scholar
• Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17(5):840–847. DOI:10.1128/CVI.00529-09
   PubMed Web of Science ®Google Scholar
• Garrido-Estepa M, Nunez OG, Leon-Gomez I, et al. Meningococcal C conjugate age-dependant long-term loss of effectiveness. Vaccine. 2015;33(19):2221–2227. DOI:10.1016/j.vaccine.2015.03.044
   PubMed Web of Science ®Google Scholar
• Garrido-Estepa M, Leon-Gomez I, Herruzo R, et al. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification. Vaccine. 2014;32(22):2604–2609. DOI:10.1016/j.vaccine.2014.03.010
   PubMed Web of Science ®Google Scholar
• Hellenbrand W, Elias J, Wichmann O, et al. Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine. J Infect. 2013;66(1):48–56. DOI:10.1016/j.jinf.2012.09.008
   PubMed Web of Science ®Google Scholar
• Krone M, Gray S, Abad R, et al. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Euro Surveill. 2019;24(14). doi: 10.2807/1560-7917.ES.2019.24.14.1800245
   PubMedGoogle Scholar
• Booy R, Gentile A, Nissen M, et al. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother. 2019;15(2):470–480. DOI:10.1080/21645515.2018.1532248
   PubMed Web of Science ®Google Scholar
• Campbell H, Edelstein M, Andrews N, et al. Emergency meningococcal ACWY vaccination program for teenagers to control group w meningococcal Disease, England, 2015-2016. Emerg Infect Dis. 2017;23(7):1184–1187. DOI:10.3201/eid2307.170236
   PubMed Web of Science ®Google Scholar
• Presa J, Findlow J, Vojicic J, et al. Epidemiologic trends, global shifts in meningococcal vaccination guidelines, and data supporting the use of MenACWY-TT vaccine: a review. Infect Dis Ther. 2019;8(3):307–333. DOI:10.1007/s40121-019-0254-1
   PubMed Web of Science ®Google Scholar
• Luca V, Gessner BD, Luca C, et al. Incidence and etiological agents of bacterial meningitis among children <5 years of age in two districts of Romania. Eur J Clin Microbiol Infect Dis. 2004;23(7):523–528. DOI:10.1007/s10096-004-1169-6
   PubMed Web of Science ®Google Scholar
• Achtman M, van der Ende A, Zhu P, et al. Molecular epidemiology of serogroup a meningitis in Moscow, 1969 to 1997. Emerg Infect Dis. 2001;7(3):420–427. DOI:10.3201/eid0703.017309
   PubMed Web of Science ®Google Scholar
• Tsolia MN, Theodoridou M, Tzanakaki G, et al. Invasive meningococcal disease in children in Greece: comparison of serogroup a disease with disease caused by other serogroups. Eur J Clin Microbiol Infect Dis. 2006;25(7):449–456. DOI:10.1007/s10096-006-0155-6
   PubMed Web of Science ®Google Scholar
• Kremastinou J, Tzanakaki G, Velonakis E, et al. Carriage of Neisseria meningitidis and Neisseria lactamica among ethnic Greek school children from Russian immigrant families in Athens. FEMS Immunol Med Microbiol. 1999;23(1):13–20. DOI:10.1111/j.1574-695X.1999.tb01711.x
   PubMedGoogle Scholar
• Balmer P, York LJ. Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control. Ther Adv Vaccines Immunother. 2018;6(3):49–60. doi: 10.1177/2515135518781757.
   PubMedGoogle Scholar
• Martinón-Torres F, Banzhoff A, Azzari C, et al. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. J Infect. 2021;83(1):17–26. doi: 10.1016/j.jinf.2021.04.031.
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Lefebvre B, et al. Impact of an immunization campaign to control an increased incidence of serogroup b meningococcal disease in one region of Quebec, Canada. Clin Infect Dis. 2017;64(9):1263–1267. DOI:10.1093/cid/cix154
   PubMed Web of Science ®Google Scholar
• Fiorito TM, Bornschein S, Mihalakos A, et al. Rapid response to a college outbreak of meningococcal serogroup B disease: nation’s first widespread use of bivalent rLP2086 vaccine. J Am Coll Health. 2017;65(4):294–296. DOI:10.1080/07448481.2017.1285772
   PubMed Web of Science ®Google Scholar
• Capitano B, Dillon K, LeDuc A, et al. Experience implementing a university-based mass immunization program in response to a meningococcal B outbreak. Hum Vaccin Immunother. 2019;15(3):717–724. DOI:10.1080/21645515.2018.1547606
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunisation, JCVI position statement on use of Bexsero® meningococcal B vaccine in the UK. [cited 2021 Nov 2]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/294245/JCVI_Statement_on_MenB.pdf.
   Google Scholar
• García FJ Á, Cilleruelo Ortega MJ, Alvarez Aldean J, et al. Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2021. Anales de Pediatría. 2021;94(1):.e53.1–.e53.10. DOI:10.1016/j.anpedi.2020.10.002
   Google Scholar
• Azzari C, Moriondo M, Nieddu F, et al. Effectiveness and Impact of the 4CMenB vaccine against group B meningococcal disease in Two Italian Regions Using Different Vaccination Schedules: a Five-Year Retrospective Observational Study. Vaccines (Basel). 2014-2018;2020(8):469. DOI:10.3390/vaccines8030469
   Google Scholar
• Sulis G, Horn M, Borrow R, et al. A comparison of national vaccination policies to prevent serogroup B meningococcal disease. Vaccine. 2022;40(26):3647–3654. DOI:10.1016/j.vaccine.2022.04.101
   PubMed Web of Science ®Google Scholar
• ECDC, Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU/EEA [cited 2021 Nov 3]. Available from: https://www.ecdc.europa.eu/en/publications-data/expert-opinion-introduction-meningococcal-b-4cmenb-vaccine-eueea.
   Google Scholar
• Rodrigues FMP, Marlow R, Joao Simoes M, et al. Association oF use of a meningococcus group B vaccine with Group B invasive meningococcal disease among children in Portugal. JAMA. 2020;324(21):2187–2194. DOI:10.1001/jama.2020.20449
   PubMed Web of Science ®Google Scholar
• Rivero-Calle I, Raguindin PF, Gomez-Rial J, et al. Meningococcal Group B Vaccine for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroup B. Infect Drug Resist. 2019;12: 3169–3188. doi: 10.2147/IDR.S159952
   PubMed Web of Science ®Google Scholar
• Moreno-Pérez D, Alvarez Garcia FJ, Aristegui Fernandez J, et al. Immunisation schedule of the Spanish Association of Paediatrics: 2016 recommendations. An Pediatr (Barc). 2016;84(1):60.e1–13. DOI:10.1016/j.anpedi.2015.10.001
   PubMedGoogle Scholar
• Calendario de Vacunaciones de la Asociación Española de Pediatría, Razones y bases de las recomendaciones 2022. Madrid: AEP; 2022. [cited 2022 Sep 12]. Available from: https://vacunasaep.org/profesionales/calendario-de-vacunaciones-de-la-aep-2022.
   Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–2782. DOI:10.1016/S0140-6736(16)31921-3
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl 1):S58–67. doi: 10.1016/S0264-410X(01)00299-7
   PubMed Web of Science ®Google Scholar
• Deceuninck G, Lefebvre B, Tsang R, et al. Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine. 2019;37(31):4243–4245. DOI:10.1016/j.vaccine.2019.06.021
   PubMed Web of Science ®Google Scholar
• Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–327. DOI:10.1056/NEJMoa1900236
   PubMed Web of Science ®Google Scholar
• Soeters HM, Whaley M, Alexander-Scott N, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination Campaign at a College-Rhode Island, 2015-2016. Clin Infect Dis. 2017;64(8):1115–1122. DOI:10.1093/cid/cix091
   PubMed Web of Science ®Google Scholar
• McNamara LA, Dolan Thomas J, MacNeil J, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal Disease Outbreak-Oregon, 2015-2016. J Infect Dis. 2017;216(9):1130–1140. DOI:10.1093/infdis/jix446
   PubMed Web of Science ®Google Scholar
• Snape MD, Saroey P, John TM, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ. 2013;185(15):E715–E724. DOI:10.1503/cmaj.130257
   PubMed Web of Science ®Google Scholar
• Carr J, Plested E, Aley P, et al. ‘Be on the TEAM’ Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. BMJ Open. 2020;10(10):e037358. DOI:10.1136/bmjopen-2020-037358
   PubMed Web of Science ®Google Scholar
• Harris SL, Donald RGK, Hawkins JC, et al. Neisseria meningitidis Serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains. Pediatr Infect Dis J. 2017;36(2):216–223. DOI:10.1097/INF.0000000000001399
   PubMed Web of Science ®Google Scholar
• Lujan E, Partridge E, Giuntini S, et al. Breadth and duration of meningococcal serum bactericidal activity in health care workers and microbiologists immunized with the MenB-FHbp Vaccine. Clin Vaccine Immunol. 2017;24(8):e00121–17. DOI:10.1128/CVI.00121-17
   PubMedGoogle Scholar
• Taha MK, Hawkins JS, Liberator P, et al. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Vaccine. 2017;35(11):1530–1537. DOI:10.1016/j.vaccine.2017.01.066
   PubMed Web of Science ®Google Scholar
• Pollard AJ, MacDonald NE, Dubé E, et al. Presentations at the UK National Immunisation Conference. Hum Vaccin Immunother. 2022;18(7):2087411.
   PubMedGoogle Scholar
• Andrianou XD, Riccardo F, Caporali MG, et al. Evaluation of the national surveillance system for invasive meningococcal disease, Italy, 2015–2018. PLoS ONE. 2021;16(1):e0244889. DOI:10.1371/journal.pone.0244889
   PubMed Web of Science ®Google Scholar
• Fox AJ, Taha MK, Vogel U. Standardized nonculture techniques recommended for European reference laboratories. FEMS Microbiol Rev. 2007;31(1):84–88. doi: 10.1111/j.1574-6976.2006.00048.x
   PubMed Web of Science ®Google Scholar
• Simões MJ, Bettencourt C, De Paola R, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal. PLoS ONE. 2017;12(5):e0176177. DOI:10.1371/journal.pone.0176177
   PubMed Web of Science ®Google Scholar
• Instituto de salud Carlos III - RENAVE, Informes Anuales de la Red Nacional de Vigilancia Epidemiológica (RENAVE) [cited 2021 Nov 9]. Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/Informes-anuales-RENAVE.aspx.
   Google Scholar